Singapore markets close in 6 hours 41 minutes

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.16+0.07 (+0.50%)
At close: 04:00PM EDT
14.16 0.00 (0.00%)
After hours: 05:27PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 42.73B
Enterprise value 68.14B
Trailing P/E 26.39
Forward P/E 9.95
PEG Ratio (5 yr expected) 0.51
Price/sales (ttm)1.70
Price/book (mrq)1.05
Enterprise value/revenue 0.02
Enterprise value/EBITDA 0.07

Trading information

Stock price history

Beta (5Y monthly) 0.90
52-week change 3-15.27%
S&P500 52-week change 3-12.23%
52-week high 317.31
52-week low 313.05
50-day moving average 314.14
200-day moving average 314.47

Share statistics

Avg vol (3-month) 32.65M
Avg vol (10-day) 32.61M
Shares outstanding 53.11B
Implied shares outstanding 6N/A
Float 83.06B
% held by insiders 10.01%
% held by institutions 11.86%
Shares short (14 Jun 2022) 44.06M
Short ratio (14 Jun 2022) 41.5
Short % of float (14 Jun 2022) 4N/A
Short % of shares outstanding (14 Jun 2022) 40.13%
Shares short (prior month 12 May 2022) 45.3M

Dividends & splits

Forward annual dividend rate 40.8
Forward annual dividend yield 45.67%
Trailing annual dividend rate 3180.00
Trailing annual dividend yield 31,277.50%
5-year average dividend yield 44.36
Payout ratio 460.92%
Dividend date 314 Dec 2009
Ex-dividend date 428 Sept 2021
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 30 Mar 2022
Most-recent quarter (mrq)30 Mar 2022


Profit margin 6.45%
Operating margin (ttm)16.80%

Management effectiveness

Return on assets (ttm)2.87%
Return on equity (ttm)4.24%

Income statement

Revenue (ttm)3.57T
Revenue per share (ttm)1,141.35
Quarterly revenue growth (yoy)13.40%
Gross profit (ttm)2.44T
Net income avi to common (ttm)230.06B
Diluted EPS (ttm)0.54
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)849.7B
Total cash per share (mrq)274.03
Total debt (mrq)4.81T
Total debt/equity (mrq)84.64
Current ratio (mrq)1.21
Book value per share (mrq)1,832.81

Cash flow statement

Operating cash flow (ttm)1.12T
Levered free cash flow (ttm)928.76B